Ticker > Company >

Norris Medicines share price

Norris Medicines Ltd.

BSE: 524414 SECTOR: Pharmaceuticals & Drugs  6792   5   1

22.98
-0.46 (-1.96%)
BSE: 31 Jan 04:01 PM

Price Summary

Today's High

₹ 22.98

Today's Low

₹ 22.98

52 Week High

₹ 27.74

52 Week Low

₹ 10.7

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

22.98 Cr.

Enterprise Value

44.47 Cr.

No. of Shares

1 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -14.28

CASH

0.04 Cr.

DEBT

21.52 Cr.

Promoter Holding

34 %

EPS (TTM)

₹  -0.82

Sales Growth

-32.57%

ROE

0 %

ROCE

-8.64%

Profit Growth

32.17 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-32.57%
3 Year-22.81%
5 Year-19.1%

Profit Growth

1 Year32.17%
3 Year20.76%
5 Year5.26%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year-8.64%
3 Year-4.02%
5 Year-9.71%

Debt/Equity

-1.5791

Price to Cash Flow

135.36

Interest Cover Ratio

-1.9685

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 34.00 0.00
Sep 2024 34.01 0.00
Jun 2024 34.01 0.00
Mar 2024 34.01 0.00
Dec 2023 34.01 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor revenue growth of -22.8050876320587% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of -4.01796999189557% over the past 3 years
  • The company has a low EBITDA margin of -6.90508208968655% over the past 5 years.
  • The company has negative book value.
  • The company is trading at a high EV/EBITDA of 248.8526.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 2.56 0.65 1.49 0.73 1.27
Total Expenditure 2.8 0.69 1 0.89 1.41
Operating Profit -0.25 -0.04 0.49 -0.16 -0.15
Other Income 0 0 0.03 0.01 0
Interest 0.09 0.09 0.11 0.08 0.09
Depreciation 0.15 0.15 0.14 0.13 0.13
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.48 -0.27 0.26 -0.37 -0.36
Tax 0 0 0.09 0 0
Profit After Tax -0.48 -0.27 0.17 -0.37 -0.36
Adjusted EPS (Rs) -0.48 -0.27 0.18 -0.37 -0.36

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 7.84 12.25 9.44 8.36 5.64
Total Expenditure 10 14 9.51 7.44 5.82
Operating Profit -2.16 -1.74 -0.07 0.92 -0.18
Other Income 0.09 0.05 0.03 0.01 0.03
Interest 0.88 1.63 1.48 1.5 0.37
Depreciation 0.73 0.67 0.66 0.63 0.57
Exceptional Items 0 0 0 0 0
Profit Before Tax -3.68 -3.99 -2.18 -1.19 -1.1
Tax -0.84 0.97 1.08 0.56 0.09
Net Profit -2.84 -4.96 -3.26 -1.75 -1.19
Adjusted EPS (Rs.) -2.86 -5 -3.29 -1.76 -1.2

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.93 9.93 9.93 9.93 9.93
Total Reserves -12.39 -17.36 -20.62 -22.37 -23.56
Borrowings 14.98 15.52 18.1 18.43 18.59
Other N/C liabilities -3.66 -2.69 -1.61 -1.05 -0.96
Current liabilities 8.04 11.69 6.78 7.7 9.23
Total Liabilities 16.9 17.1 12.58 12.63 13.22
Assets
Net Block 8.25 7.67 7.07 6.47 5.79
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.01
Loans & Advances 1.2 1.19 1.23 1.23 1.29
Other N/C Assets 0 0 0 0 0
Current Assets 7.44 8.23 4.27 4.92 6.14
Total Assets 16.9 17.1 12.58 12.63 13.22
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -3.68 -3.99 -2.18 -1.19 -1.1
Adjustment 1.59 2.29 2.13 2.12 0.95
Changes in Assets & Liabilities -0.79 2.82 -0.95 0.27 0.32
Tax Paid 0 0 0 0 0
Operating Cash Flow -2.88 1.11 -1.01 1.2 0.17
Investing Cash Flow 0 -0.06 -0.09 -0.02 0.05
Financing Cash Flow 2.86 -1.09 1.1 -1.18 -0.2
Net Cash Flow -0.02 -0.04 0 0 0.02

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 34.01 34.01 34.01 34.01 34.00
dhirendra kantilal shah h... - - - 0.34 0.34
milind l upadhyaya 0.01 0.01 0.01 0.01 0.01
navnit jethabhai patel 0.04 0.04 0.04 0.04 0.04
navsarjan investment & tr... 10.00 10.00 10.00 10.00 10.00
vimal d shah 23.60 23.60 23.60 23.60 23.60
nimish bhishma thakore 0.01 0.01 0.01 0.01 -
vimal dhirendra shah 0.34 0.34 0.34 - -
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 65.99 65.99 65.99 65.99 66.00
fab metals private limite... 41.99 41.99 41.99 41.99 41.99
lkp securities limited 1.50 1.50 1.50 1.50 1.50

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Norris Medicines informs about newspaper publication 10 Sep, 4:39 PM Norris Medicines - Quaterly Results 14 Aug, 4:53 PM Norris Medicines informs about change in management 3 Jul, 1:07 PM Norris Medicines informs about outcome of directors meeting 22 Mar, 5:24 PM Norris Medicines - Quaterly Results 14 Feb, 3:40 PM Norris Medicines - Quaterly Results 14 Feb, 3:40 PM Norris Medicines informs about closure of trading window 29 Sep, 4:55 PM Norris Medicines - Quaterly Results 10 Aug, 4:40 PM Norris Medicines - Quaterly Results 10 Aug, 4:40 PM Norris Medicines informs about issuance of duplicate share certificate 14 Jun, 4:55 PM Norris Medicines - Quaterly Results 25 May, 3:37 PM Norris Medicines - Quaterly Results 25 May, 3:37 PM Norris Medicines - Quaterly Results 25 May, 3:37 PM Norris Medicines informs about outcome of board meeting 13 Feb, 4:38 PM Norris Medicines - Quaterly Results 13 Feb, 12:39 PM Norris Medicines - Quaterly Results 13 Feb, 12:39 PM Norris Medicines - Quaterly Results 13 Feb, 12:39 PM Norris Medicines informs about unaudited financial results 11 Nov, 5:14 PM Norris Medicines - Quaterly Results 11 Nov, 11:25 AM Norris Medicines informs about outcome of board meeting 15 Sep, 5:13 PM Norris Medicines - Quaterly Results 27 Aug, 5:27 PM Norris Medicines - Quaterly Results 27 Aug, 5:27 PM Norris Medicines - Quaterly Results 27 Aug, 5:27 PM Norris Medicines - Quaterly Results 25 May, 2:54 PM Norris Medicines - Quaterly Results 25 May, 2:54 PM Norris Medicines - Quaterly Results 25 May, 2:54 PM Norris Medicines informs about PCS certificate 20 Apr, 4:48 PM Norris Medicines informs about compliance certificate 5 Apr, 5:02 PM Norris Medicines - Quaterly Results 12 Feb, 1:50 PM Norris Medicines informs about trading window closure 31 Dec, 3:49 PM Norris Medicines informs about book closure 28 Aug, 2:38 PM Norris Medicines informs about notice of 30th AGM 28 Aug, 12:59 PM Norris Medicines informs about compliance certificate 5 Jul, 12:50 PM Norris Medicines informs about non-applicability of annual secretarial compliance report 28 Jun, 4:25 PM Norris Medicines informs about board meeting 19 Jun, 11:35 AM Norris Medicines informs about demise of independent director 24 May, 12:34 PM Norris Medicines submits certificate 20 Apr, 3:30 PM Norris Medicines informs about compliance certificate 3 Oct, 3:47 PM Norris Medicines submits voting result of AGM 26 Sep, 3:53 PM Norris Medicines informs about disclosure of material impact of covid-19 1 Jun, 3:52 PM

Norris Medicines Stock Price Analysis and Quick Research Report. Is Norris Medicines an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Norris Medicines and its performance over the period of time. Norris Medicines stock price today is Rs 22.98.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Norris Medicines cash from the operating activity was Rs 0.1697854 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Norris Medicines has a Debt to Equity ratio of -1.5791 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Norris Medicines , the EPS growth was 32.1684 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Norris Medicines has OPM of -3.28131444784139 % which is a bad sign for profitability.
     
  • ROE: Norris Medicines have a poor ROE of 0 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Norris Medicines is Rs 22.98. One can use valuation calculators of ticker to know if Norris Medicines share price is undervalued or overvalued.
Last Updated on:
Brief about Norris Medicines
X